Vascular Biogenics Ltd. (VBLT) |
|
1.63 0.02 (1.24%)
|
07-02 16:17 |
|
Open: |
1.6138 |
Pre. Close: |
1.61 |
|
High:
|
1.64 |
Low:
|
1.58 |
|
Volume:
|
89,527 |
Market Cap:
|
113(M) |
|
|
|
|
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.64 - 1.65 |
1.65 - 1.65 |
|
Low:
|
1.56 - 1.57 |
1.57 - 1.58 |
|
Close:
|
1.62 - 1.63 |
1.63 - 1.64 |
|
Technical analysis |
as of: 2022-07-01 4:25:59 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 2.28 One year: 2.67 |
| Support: |
Support1: 1.5 Support2: 1.21 |
| Resistance: |
Resistance1: 1.96 Resistance2: 2.28 |
| Pivot: |
1.44  |
| Moving Average: |
MA(5): 1.59 MA(20): 1.46
MA(100): 1.51 MA(250): 1.85  |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 84.7 %D(3): 84 |
| RSI: |
RSI(14): 59.6 |
| 52-week: |
High: 2.58 Low: 1.1 |
| Average Vol(K): |
3-Month: 178 (K) 10-Days: 109 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VBLT ] has closed below upper band by 9.7%. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sat, 02 Jul 2022
Vascular Biogenics (NASDAQ:VBLT) Shares Pass Above Fifty Day Moving Average of $1.54 - Defense World
Sat, 02 Jul 2022
Vascular Biogenics (NASDAQ:VBLT) Now Covered by StockNews.com - MarketBeat
Thu, 30 Jun 2022
VBL Therapeutics to Participat - GuruFocus.com
Thu, 16 Jun 2022
Vascular Biogenics (NASDAQ:VBLT) Coverage Initiated by Analysts at StockNews.com - Defense World
Fri, 10 Jun 2022
Vascular Biogenics (NASDAQ:VBLT) Upgraded by Zacks Investment Research to Hold - Defense World
Fri, 03 Jun 2022
Weekly Analysts' Ratings Changes for Vascular Biogenics (VBLT) - Defense World
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
69 (M) |
|
% Held by Insiders
|
4.641e+007 (%) |
|
% Held by Institutions
|
23.9 (%) |
|
Shares Short
|
557 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.874e+007 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.75 |
|
EPS Est Next Year
|
-0.78 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-3 |
|
Return on Assets (ttm)
|
905.7 |
|
Return on Equity (ttm)
|
-35.3 |
|
Qtrly Rev. Growth
|
768000 |
|
Gross Profit (p.s.)
|
-3.83 |
|
Sales Per Share
|
-63.86 |
|
EBITDA (p.s.)
|
350435 |
|
Qtrly Earnings Growth
|
-0.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-25 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.03 |
|
Price to Cash Flow
|
2.37 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
688030 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
